SUBSCRIBE
SUBSCRIBE

Biohaven

NEWS
Drug Development
Clinical Catch-Up for July 8-12
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
July 12, 2019
 · 
5 min read
 · 
Mark Terry
Business
Licensing Deals: Biohaven and AstraZeneca, Roivant and Patara, Gilead and Trianni
A number of companies are making the transition from the third quarter to the fourth quarter with licensing deals to bolster their pipelines. Here’s a look at just a few of them.
September 5, 2018
 · 
3 min read
 · 
Mark Terry
Drug Development
Biohaven Reports Positive Early Clinical Trial Results for Anxiety Drug
Biohaven Pharma, headquartered in New Haven, Conn., announced positive data from a proof-of-concept trial for its BHV-0223 in social anxiety and public speaking anxiety disorders.
August 16, 2018
 · 
3 min read
 · 
Mark Terry
Virtual brain innovative technology in science and medical concept in blue tone
Drug Development
Stock Plunges Despite Biohaven’s Positive Migraine Data
Biohaven Pharmaceutical released positive top-line results from two Phase III clinical trials of rimegepant for migraine. Despite the positive data, shares were down more than 30 percent in early trading this morning.
March 26, 2018
 · 
3 min read
 · 
Mark Terry
Gemini Therapeutics Banks $42.5M to Bring Precisio
Deals
The 2017 Biotech IPO Winners and Losers
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.
December 21, 2017
 · 
4 min read
 · 
Mark Terry
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
Biohaven Eyes $100 Million IPO to Bankroll Trials of Shelved AstraZeneca PLC, Bristol-Myers Squibb Drugs
April 10, 2017
 · 
3 min read
Load More
JOBS
IN THE PRESS
Deals
Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences
February 25, 2022
 · 
8 min read
Drug Development
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
February 25, 2022
 · 
6 min read
Drug Development
Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT
February 22, 2022
 · 
6 min read
Business
BIOHAVEN TO REPORT FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ON FEBRUARY 25, 2022
February 16, 2022
 · 
2 min read
Business
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
February 14, 2022
 · 
12 min read
Pharm Country
NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia Reports
February 3, 2022
 · 
7 min read
Business
Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain
January 10, 2022
 · 
7 min read
Business
Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States
January 5, 2022
 · 
12 min read
Pharm Country
BIOHAVEN ANNOUNCES NURTEC® ODT RECEIVES FIRST GLOBAL APPROVAL OUTSIDE THE U.S. FOR PREVENTION OF MIGRAINE
December 13, 2021
 · 
6 min read
Business
Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer
December 6, 2021
 · 
4 min read
Load More